Coexpression of cyclooxygenase-2 and matrix metallop atherosclerotic lesions

Yonsei Medical Journal 41, 82 DOI: 10.3349/ymj.2000.41.1.82

Citation Report

#	Article	IF	CITATIONS
1	Plasmin and Matrix Metalloproteinases in Vascular Remodeling. Thrombosis and Haemostasis, 2001, 86, 324-333.	3.4	399
2	Prostaglandin H Synthase and Vascular Function. Circulation Research, 2001, 89, 650-660.	4.5	209
3	Tumor Necrosis Factor Receptor Superfamily 14 Is Involved in Atherogenesis by Inducing Proinflammatory Cytokines and Matrix Metalloproteinases. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 2004-2010.	2.4	120
4	Cyclooxygenase-2 Is Induced in Monocytes by Peroxisome Proliferator Activated Receptor γ and Oxidized Alkyl Phospholipids from Oxidized Low Density Lipoprotein. Journal of Biological Chemistry, 2002, 277, 13029-13036.	3.4	94
5	Reduced Atherosclerotic Plaque but Enhanced Aneurysm Formation in Mice With Inactivation of the Tissue Inhibitor of Metalloproteinase-1 (<i>TIMP-1</i>) Gene. Circulation Research, 2002, 90, 897-903.	4.5	180
6	Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis, 2002, 160, 49-58.	0.8	116
7	The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. European Journal of Surgical Oncology, 2002, 28, 729-737.	1.0	58
8	Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: An immunohistochemical study. Human Pathology, 2002, 33, 1158-1164.	2.0	26
9	Tissue Levels of Matrix Metalloproteinases in Pulps and Periapical Lesions. Journal of Endodontics, 2002, 28, 313-315.	3.1	118
10	Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. British Journal of Haematology, 2002, 119, 38-45.	2.5	39
11	CD40 ligation triggers COX-2 expression in endothelial cells: evidence that CD40-mediated IL-6 synthesis is COX-2-dependent. Inflammation Research, 2003, 52, 18-25.	4.0	17
12	Acute coronary disease Athero-Inflammation: Therapeutic approach. , 2003, 1, 2.		10
13	Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. American Heart Journal, 2003, 146, 591-604.	2.7	122
14	Cyclooxygenase isoforms and atherosclerosis. Expert Reviews in Molecular Medicine, 2003, 5, 1-18.	3.9	27
15	Metalloproteinases in Development and Progression of Vascular Disease. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 275-281.	0.3	87
16	Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 246-255.	2.4	135
17	Increased cyclooxygenase-2 expression in peripheral blood mononuclear cells of smokers and hyperlipidemic subjects. Free Radical Biology and Medicine, 2005, 38, 235-242.	2.9	20
18	Omega-3 Fatty Acids and the Regulation of Expression of Endothelial Pro-Atherogenic and Pro-Inflammatory Genes. Journal of Membrane Biology, 2005, 206, 103-116.	2.1	115

#	Article	IF	Citations
19	Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. Journal of Cell Science, 2005, 118, 343-356.	2.0	214
20	Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, Decreases Monocyte Chemoattractant Protein-1 Expression and Neointimal Hyperplasia in the Rabbit Atherosclerotic Balloon Injury Model. Journal of Cardiovascular Pharmacology, 2005, 45, 61-67.	1.9	38
21	The PGH-Synthase System and Isozyme-selective Inhibition. Journal of Cardiovascular Pharmacology, 2006, 47, S1-S6.	1.9	22
22	Innovative Dietary Sources of N-3 Fatty Acids. Annual Review of Nutrition, 2006, 26, 75-103.	10.1	168
23	Cyclooxygenase-2 inhibition: Vascular inflammation and cardiovascular risk. Current Atherosclerosis Reports, 2006, 8, 245-251.	4.8	17
24	Salvianolic acid B attenuates cyclooxygenase-2 expression in vitro in LPS-treated human aortic smooth muscle cells and in vivo in the apolipoprotein-E-deficient mouse aorta. Journal of Cellular Biochemistry, 2006, 98, 618-631.	2.6	73
25	Z39Ig is expressed on macrophages and may mediate inflammatory reactions in arthritis and atherosclerosis. Journal of Leukocyte Biology, 2006, 80, 922-928.	3.3	45
26	Endothelial Functions and Dysfunctions. , 0, , 1-25.		9
27	Distribution Profiles of Membrane Type-1 Matrix Metalloproteinase (MT1-MMP), Matrix Metalloproteinase-2 (MMP-2) and Cyclooxygenase-2 (COX-2) in Rabbit Atherosclerosis: Comparison with Plaque Instability Analysis. Biological and Pharmaceutical Bulletin, 2007, 30, 1634-1640.	1.4	39
28	Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H28-H42.	3.2	71
29	Balancing prostanoid activity in the human vascular system. Trends in Pharmacological Sciences, 2007, 28, 106-110.	8.7	94
30	Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 45-54.	2.4	36
31	Cyclooxygenase-2 Expression and Its Association with Increased Angiogenesis in Human Abdominal Aortic Aneurysms. Annals of Vascular Surgery, 2007, 21, 61-66.	0.9	15
32	The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Research and Treatment, 2008, 109, 189-198.	2.5	108
33	The Select Cyclooxygenase-2 Inhibitor Celecoxib Reduced the Extent of Atherosclerosis in Apo E-/- Mice. Journal of Surgical Research, 2008, 146, 135-142.	1.6	35
34	Omega–3 Fatty Acids, Inflammation and Angiogenesis: Nutrigenomic Effects as an Explanation for Anti-Atherogenic and Anti-Inflammatory Effects of Fish and Fish Oils. Journal of Nutrigenetics and Nutrigenomics, 2008, 1, 4-23.	1.3	29
35	Expression analysis of matrix metalloproteinase-9 in epithelialized and nonepithelialized apical periodontitis lesions. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2009, 107, 127-132.	1.4	36
36	Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Experimental and Molecular Medicine, 2009, 41, 802.	7.7	31

CITATION REPORT

#	Article	IF	CITATIONS
37	The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE2 pathway. Inflammation Research, 2010, 59, 1033-1040.	4.0	7
38	Gender Differences in Cardiovascular Disease: Hormonal and Biochemical Influences. Reproductive Sciences, 2010, 17, 511-531.	2.5	155
39	Pathophysiology of Cyclooxygenases in Cardiovascular Homeostasis. Veterinary Pathology, 2010, 47, 601-613.	1.7	29
40	Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovascular Research, 2010, 86, 311-320.	3.8	101
41	Functional genetic variations of cyclooxygenase-2 and susceptibility to acute myeloid leukemia in a Chinese population. European Journal of Haematology, 2011, 87, 486-493.	2.2	18
42	Aging-Shifted Prostaglandin Profile in Endothelium as a Factor in Cardiovascular Disorders. Journal of Aging Research, 2012, 2012, 1-16.	0.9	26
43	Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: A potentially protective mechanism in atherosclerotic vascular disease and cancer. Archives of Biochemistry and Biophysics, 2012, 527, 81-89.	3.0	275
44	Targeting the Tumor Microenvironment: Focus on Angiogenesis. Journal of Oncology, 2012, 2012, 1-16.	1.3	93
45	Most Relevant Polyphenols Present in the Mediterranean Diet and Their Incidence in Cancer Diseases. , 2014, , 1341-1351.		1
46	Atherosclerosis and Mediterranean Diet Polyphenols. , 2014, , 895-903.		1
47	Up-regulation of COX-2 and mPGES-1 by 27-hydroxycholesterol and 4-hydroxynonenal: A crucial role in atherosclerotic plaque instability. Free Radical Biology and Medicine, 2018, 129, 354-363.	2.9	15
48	Cardio-renal safety of non-steroidal anti-inflammatory drugs. Journal of Toxicological Sciences, 2019, 44, 373-391.	1.5	39
49	In Vitro Biomarker Discovery for Atherosclerosis by Proteomics. Molecular and Cellular Proteomics, 2004, 3, 1200-1210.	3.8	82
50	Cyclooxygenease-2 and breast cancer. Cancer Metastasis - Biology and Treatment, 2007, , 259-277.	0.1	0
52	microRNA-223 and microRNA-126 are clinical indicators for predicting the plaque stability in carotid atherosclerosis patients. Journal of Human Hypertension, 2023, 37, 788-795.	2.2	2

4